Georgy V. Sholokhov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Georgy V. Sholokhov has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Dzerasa G. Khaimanova
Saint Petersburg Clinical Hospital of the Russian Academy of Sciences
3 shared publications - Daria I. Kozlova
Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences
2 shared publications - Sergey O. Kuzin
Saint Petersburg Clinical Hospital
2 shared publications - Vitaliy V. Khizha
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences (IEFB RAS), Autoimmune and Autoinflammation Human Diseases Investigation Scientific and Practical Research Group, Saint- Petersburg, 194223, Russian Federation
2 shared publications Шолохов Георгий Владимирович
Санкт-Петербургская клиническая больница Российской академии наук
2 shared publications- A. G. Vasiliev
St. Petersburg Clinical Hospital of the Russian Academy of Sciences
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by ECO-Vector LLC (Publications) in Medical academic journal
- Vol. 25 (4) , 93-106
Prognostic markers of immune-related adverse events in cancer therapy with checkpoint inhibitors: an uncontrolled, open-label, prospective cohort study
BACKGROUND: Immune checkpoint inhibitors are highly effective in treating malignant neoplasms, but they often cause immune-related adverse events. The mechanisms of their pathogenesis are not well understood, and there are no reliable markers in clinical practice for assessing the risk of their occurrence. This study addresses the lack of research by validating a panel of markers. This will allow for personalized preventive management of patients and reduce the frequency of premature treatment discontinuation. AIM: The study aimed to identify the most informative prognostic markers for immune-related adverse events by evaluating dynamic changes in plasma cytokine levels in patients with malignant neoplasms who were receiving checkpoint inhibitor therapy. METHODS: A prospective study of patients with malignant neoplasms receiving checkpoint inhibitor therapy was conducted between 2023 and 2024 at the St. Petersburg Hospital of the Russian Academy of Sciences. The risk of immune-related adverse events was assessed as part of the dynamic observation (105 days with 2.0–2.5-week intervals). The primary endpoint was changes in plasma cytokine concentrations, determined by multiplex analysis and analyzed using nonparametric statistical tests such as the Shapiro–Wilk test, Mann–Whitney U test, and Šidák correction. RESULTS: The study included 21 patients with malignant neoplasms who completed the entire observation program. Six patients (28.6%) developed immune-related adverse events, whereas 15 (71.4%) did not. The development of immune-related adverse events was found to be associated with a significant increase in cytokine concentrations, suggesting a predominance of type 1 and type 17 T-helper cells. Of the evaluated biomarkers, interleukin 12p70 (IL-12p70), IL-15, and transforming growth factor-beta (TGF-β) had the greatest prognostic value for predicting complications. These biomarkers exhibited high sensitivity and specificity in pairwise group comparisons (p 0.005). During the manifestation of immune-related adverse events, the plasma concentrations of the following markers were as follows: IL 12p70: 2.51 [2.09–2.93] pg/mL; TGF-β: 14.54 [13.52–17.12] ng/mL; IL-15: 20.86 [15.51–26.21] pg/mL. The analysis confirmed that these markers are the most reliable predictors of an excessive immune response. No complications unrelated to the primary mechanism of action of the study therapy were reported. CONCLUSION: This study demonstrated for the first time the possibility of a predictive risk assessment for immune-related adverse events prior to checkpoint inhibitor therapy initiation based on IL-12p70, IL-15, and TGF-β levels. These findings allow for personalized patient management strategies that balance treatment efficacy with the prevention of complications. The study had two main limitations: its small sample size (n = 21) and the fact that patients were recruited from a single site.
- 26 December 2025
- Published by ECO-Vector LLC (Publications) in Medical academic journal
- Vol. 25 (4) , 93-106
Open AccessPrognostic markers of immune-related adverse events in cancer therapy with checkpoint inhibitors: an uncontrolled, open-label, prospective cohort study
BACKGROUND: Immune checkpoint inhibitors are highly effective in treating malignant neoplasms, but they often cause immune-related adverse events. The mechanisms of their pathogenesis are not well understood, and there are no reliable markers in clinical practice for assessing the risk of their occurrence. This study addresses the lack of research by validating a panel of markers. This will allow for personalized preventive management of patients and reduce the frequency of premature treatment discontinuation. AIM: The study aimed to identify the most informative prognostic markers for immune-related adverse events by evaluating dynamic changes in plasma cytokine levels in patients with malignant neoplasms who were receiving checkpoint inhibitor therapy. METHODS: A prospective study of patients with malignant neoplasms receiving checkpoint inhibitor therapy was conducted between 2023 and 2024 at the St. Petersburg Hospital of the Russian Academy of Sciences. The risk of immune-related adverse events was assessed as part of the dynamic observation (105 days with 2.0–2.5-week intervals). The primary endpoint was changes in plasma cytokine concentrations, determined by multiplex analysis and analyzed using nonparametric statistical tests such as the Shapiro–Wilk test, Mann–Whitney U test, and Šidák correction. RESULTS: The study included 21 patients with malignant neoplasms who completed the entire observation program. Six patients (28.6%) developed immune-related adverse events, whereas 15 (71.4%) did not. The development of immune-related adverse events was found to be associated with a significant increase in cytokine concentrations, suggesting a predominance of type 1 and type 17 T-helper cells. Of the evaluated biomarkers, interleukin 12p70 (IL-12p70), IL-15, and transforming growth factor-beta (TGF-β) had the greatest prognostic value for predicting complications. These biomarkers exhibited high sensitivity and specificity in pairwise group comparisons (p 0.005). During the manifestation of immune-related adverse events, the plasma concentrations of the following markers were as follows: IL 12p70: 2.51 [2.09–2.93] pg/mL; TGF-β: 14.54 [13.52–17.12] ng/mL; IL-15: 20.86 [15.51–26.21] pg/mL. The analysis confirmed that these markers are the most reliable predictors of an excessive immune response. No complications unrelated to the primary mechanism of action of the study therapy were reported. CONCLUSION: This study demonstrated for the first time the possibility of a predictive risk assessment for immune-related adverse events prior to checkpoint inhibitor therapy initiation based on IL-12p70, IL-15, and TGF-β levels. These findings allow for personalized patient management strategies that balance treatment efficacy with the prevention of complications. The study had two main limitations: its small sample size (n = 21) and the fact that patients were recruited from a single site.
- Open Access
- 20 November 2024
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 27 (5) , 451-460
DRAMS — the new system for predicting type 2 diabetes mellitus remission after baritaric surgery
BACKGROUND: Bariatric surgery has proven effective as a treatment for the metabolic complications of obesity, including type 2 diabetes mellitus (T2DM). Nowadays it is important to develop a personalized approach for bariatric patients generally, and for those with T2DM.AIM: Development of a scale for preoperative prediction of remission of T2DM in obese patients Russian population undergoing bariatric surgery (sleeve gastrectomy or gastric bypass).MATERIALS AND METHODS: A retrospective multicenter cohort study was conducted. The study included 112 patients (75 women and 37 men), mean age 46.25±9.29 years, mean BMI 48.71±7.66 kg/m2. A mathematical analysis of 17 preoperative clinical criteria was carried out to search for independent predictors of T2DM remission.RESULTS: A remission of T2DM was verified in 85 subjects, (75.9%), absence of remission of T2DM — in 27 subjects (24.1%). The most important prognostic factors were T2DM experience, age, HOMA-IR insulin resistance index, HbA1c, BMI, metformin therapy, SUs, insulin intake, increased levels of liver transaminases, and total cholesterol levels. The relative importance coefficient of each parameter was calculated. A formula has been developed to predict the high or low probability of T2DM remission after bariatric treatment. An online DRAMS (Diabetes Remission After Metabolic Surgery) calculator was proposed based on this formula so it is easy to use in clinical practice.CONCLUSION: An online calculator has been developed to predict the probability of T2DM remission after bariatric surgery. The received data allow us to construct a qualitative “high risk”/“low risk” scale. A number of identified predictors require further study in larger samples of patients.
- 20 November 2024
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 27 (5) , 451-460
Open AccessDRAMS — the new system for predicting type 2 diabetes mellitus remission after baritaric surgery
BACKGROUND: Bariatric surgery has proven effective as a treatment for the metabolic complications of obesity, including type 2 diabetes mellitus (T2DM). Nowadays it is important to develop a personalized approach for bariatric patients generally, and for those with T2DM.AIM: Development of a scale for preoperative prediction of remission of T2DM in obese patients Russian population undergoing bariatric surgery (sleeve gastrectomy or gastric bypass).MATERIALS AND METHODS: A retrospective multicenter cohort study was conducted. The study included 112 patients (75 women and 37 men), mean age 46.25±9.29 years, mean BMI 48.71±7.66 kg/m2. A mathematical analysis of 17 preoperative clinical criteria was carried out to search for independent predictors of T2DM remission.RESULTS: A remission of T2DM was verified in 85 subjects, (75.9%), absence of remission of T2DM — in 27 subjects (24.1%). The most important prognostic factors were T2DM experience, age, HOMA-IR insulin resistance index, HbA1c, BMI, metformin therapy, SUs, insulin intake, increased levels of liver transaminases, and total cholesterol levels. The relative importance coefficient of each parameter was calculated. A formula has been developed to predict the high or low probability of T2DM remission after bariatric treatment. An online DRAMS (Diabetes Remission After Metabolic Surgery) calculator was proposed based on this formula so it is easy to use in clinical practice.CONCLUSION: An online calculator has been developed to predict the probability of T2DM remission after bariatric surgery. The received data allow us to construct a qualitative “high risk”/“low risk” scale. A number of identified predictors require further study in larger samples of patients.
- Open Access
- 15 September 2024
- Published by ECO-Vector LLC in Cytokines and inflammation
- Vol. 21 (3) , 169-177
Plasma Cytokine Levels in Patient with Multiple Immune-Related Adverse Events During Nivolumab Therapy for Metastatic Cutaneous Melanoma
Nivolumab, like other immune checkpoint inhibitors, is effective in the treatment of malignant neoplasms. However, there is a growing number of reports describing the development of immune-related adverse events associated with cytokine imbalance, including myocarditis, pericarditis, pneumonitis, myositis, joint involvement, intestinal lesions, and thyroiditis, characterized by spontaneity and a reactive course. It has been hypothesized that such events are related to the disinhibition of the immune system and the development of inflammation via an autoimmune mechanism, involving the patient’s own healthy tissues and organs due to cross-reactivity in the setting of cytokine imbalance. We observed a 65-year-old woman over a 4-year period, beginning in 2019, when she first presented with complaints of a bleeding pigmented lesion on the right lower leg, later classified as cutaneous pigmented melanoma (nodular type, with ulceration and mitotic activity). She remained under observation for 2 years, and in 2021, following disease progression, she underwent 7 cycles of nivolumab therapy. Shortly thereafter, the patient reported a deterioration in her condition. From August 2021 to early 2022, she developed acute myocarditis and pericarditis, pneumonitis, myositis, a hematologic syndrome, skin induration of the extremities, and polyneuropathy. The patient was hospitalized in the rheumatology department. Researchers from the scientific department conducted a plasma cytokine study to determine the levels of several cytokines previously found to be elevated in patients with autoimmune diseases. Plasma analysis revealed increased levels of interleukin-1β, MIG, PDGF-AB/BB, RANTES, and TGF-α. These findings indicated an intermediate type of inflammatory response: less controlled than in patients without adverse effects but not reaching the level of autoimmune inflammation observed in rheumatoid arthritis. A hypothesis was proposed regarding the development of a hybrid inflammatory process, combining a systemic component of the oncologic disease and hyperactivation of the Th17 response, with a predominance of proinflammatory mediators’ characteristic of autoimmune pathologies. Nivolumab was discontinued, and comprehensive therapy was initiated to manage the cardiologic, neurologic, and rheumatic complications. Remission of the primary disease (melanoma) was achieved.
- 15 September 2024
- Published by ECO-Vector LLC in Cytokines and inflammation
- Vol. 21 (3) , 169-177
Open AccessPlasma Cytokine Levels in Patient with Multiple Immune-Related Adverse Events During Nivolumab Therapy for Metastatic Cutaneous Melanoma
Nivolumab, like other immune checkpoint inhibitors, is effective in the treatment of malignant neoplasms. However, there is a growing number of reports describing the development of immune-related adverse events associated with cytokine imbalance, including myocarditis, pericarditis, pneumonitis, myositis, joint involvement, intestinal lesions, and thyroiditis, characterized by spontaneity and a reactive course. It has been hypothesized that such events are related to the disinhibition of the immune system and the development of inflammation via an autoimmune mechanism, involving the patient’s own healthy tissues and organs due to cross-reactivity in the setting of cytokine imbalance. We observed a 65-year-old woman over a 4-year period, beginning in 2019, when she first presented with complaints of a bleeding pigmented lesion on the right lower leg, later classified as cutaneous pigmented melanoma (nodular type, with ulceration and mitotic activity). She remained under observation for 2 years, and in 2021, following disease progression, she underwent 7 cycles of nivolumab therapy. Shortly thereafter, the patient reported a deterioration in her condition. From August 2021 to early 2022, she developed acute myocarditis and pericarditis, pneumonitis, myositis, a hematologic syndrome, skin induration of the extremities, and polyneuropathy. The patient was hospitalized in the rheumatology department. Researchers from the scientific department conducted a plasma cytokine study to determine the levels of several cytokines previously found to be elevated in patients with autoimmune diseases. Plasma analysis revealed increased levels of interleukin-1β, MIG, PDGF-AB/BB, RANTES, and TGF-α. These findings indicated an intermediate type of inflammatory response: less controlled than in patients without adverse effects but not reaching the level of autoimmune inflammation observed in rheumatoid arthritis. A hypothesis was proposed regarding the development of a hybrid inflammatory process, combining a systemic component of the oncologic disease and hyperactivation of the Th17 response, with a predominance of proinflammatory mediators’ characteristic of autoimmune pathologies. Nivolumab was discontinued, and comprehensive therapy was initiated to manage the cardiologic, neurologic, and rheumatic complications. Remission of the primary disease (melanoma) was achieved.
- Open Access
- 4 July 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (3)
The Characteristics of Cardiovascular Adverse Events in Therapy with Immune Checkpoint Inhibitors: The Result of Work of the Multi-Disciplinary Team
Введение. С целью оценки характера и частоты встречаемости сердечно-сосудистых нежелательных явлений (НЯ), возникших на фоне терапии ингибиторами иммунных контрольных точек (ИИКТ), в сравнении с таковыми при лечении онкологических больных известными кардиотоксическими химиопрепаратами (КТ-ХТ), проведено открытое обсервационное ретроспективное и проспективное исследование на базе онкологического отделения в многопрофильном лечебном учреждении. Материалы и методы. В исследование включены 2 группы — 88 пациентов, получающих терапию ИИКТ и 102 пациента, получающих КТ-ХТ. Оценивались сердечные маркеры, ЭКГ, суточное мониторирование ЭКГ, эхокардиография. В случае развития острых кардиотоксических НЯ с целью дифференциальной диагностики сердечно-сосудистых иммунных нежелательных явлений выполняли магнитно-резонансную томографию сердца, коронароангиографию, вентрикулографию, ангиографию периферических артерий. Для проведения стандартного статистического анализа использовали критерий хи-квадрат и тест Манна-Уитни. Результаты. Во время противоопухолевой терапии сердечно-сосудистые НЯ — острый коронарный синдром, сердечная недостаточность, нарушения ритма; осложнения, способствующие опосредованной кардиотоксичности — ухудшение функции почек, тиреопатии и смерть от несердечно-сосудистых причин в группах иммунотерапии и КТ-ХТ встретились с примерно одинаковой частотой. Всего выявлено 109 осложнений (в среднем — 1,9 НЯ) у 58 пациентов из 88 (65,9 %) группы иммунотерапии и 110 НЯ — у 60 пациентов (58,8 %, в среднем — 1,8 НЯ) группы КТ-ХТ. Миокардит диагностирован в 5,6 %, смерть от сердечно-сосудистых причин — 5,6 %, перикардит — 3,4 % случаев. Эти осложнения встретились только в группе ИИКТ-терапии. Заключение. Терапию препаратами из группы ИИКТ можно отнести к кардиотоксической противоопухолевой терапии, т. к. частота возникающих сердечно-сосудистых осложнений при иммунотерапии сопоставима с КТ-ХТ. Причины развития кардиотоксических НЯ не обязательно являются иммуноопосредованными, но могут быть проявлениями ухудшения течения сердечно-сосудистых заболеваний, непрямой кардиотоксичности или течения собственно онкологического процесса, поэтому требуется проведение своевременной дифференциальной диагностики, разработки стратегий профилактики, обоснованного лечения возникших сердечно-сосудистых нарушений и дальнейшего ведения больных. Для достижения этих целей необходимостью является организация междисциплинарных команд с участием кардиологов/кардиоонкологов и других специалистов, участвующих в работе междисциплинарных консилиумов.
- 4 July 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (3)
Open AccessThe Characteristics of Cardiovascular Adverse Events in Therapy with Immune Checkpoint Inhibitors: The Result of Work of the Multi-Disciplinary Team
Введение. С целью оценки характера и частоты встречаемости сердечно-сосудистых нежелательных явлений (НЯ), возникших на фоне терапии ингибиторами иммунных контрольных точек (ИИКТ), в сравнении с таковыми при лечении онкологических больных известными кардиотоксическими химиопрепаратами (КТ-ХТ), проведено открытое обсервационное ретроспективное и проспективное исследование на базе онкологического отделения в многопрофильном лечебном учреждении. Материалы и методы. В исследование включены 2 группы — 88 пациентов, получающих терапию ИИКТ и 102 пациента, получающих КТ-ХТ. Оценивались сердечные маркеры, ЭКГ, суточное мониторирование ЭКГ, эхокардиография. В случае развития острых кардиотоксических НЯ с целью дифференциальной диагностики сердечно-сосудистых иммунных нежелательных явлений выполняли магнитно-резонансную томографию сердца, коронароангиографию, вентрикулографию, ангиографию периферических артерий. Для проведения стандартного статистического анализа использовали критерий хи-квадрат и тест Манна-Уитни. Результаты. Во время противоопухолевой терапии сердечно-сосудистые НЯ — острый коронарный синдром, сердечная недостаточность, нарушения ритма; осложнения, способствующие опосредованной кардиотоксичности — ухудшение функции почек, тиреопатии и смерть от несердечно-сосудистых причин в группах иммунотерапии и КТ-ХТ встретились с примерно одинаковой частотой. Всего выявлено 109 осложнений (в среднем — 1,9 НЯ) у 58 пациентов из 88 (65,9 %) группы иммунотерапии и 110 НЯ — у 60 пациентов (58,8 %, в среднем — 1,8 НЯ) группы КТ-ХТ. Миокардит диагностирован в 5,6 %, смерть от сердечно-сосудистых причин — 5,6 %, перикардит — 3,4 % случаев. Эти осложнения встретились только в группе ИИКТ-терапии. Заключение. Терапию препаратами из группы ИИКТ можно отнести к кардиотоксической противоопухолевой терапии, т. к. частота возникающих сердечно-сосудистых осложнений при иммунотерапии сопоставима с КТ-ХТ. Причины развития кардиотоксических НЯ не обязательно являются иммуноопосредованными, но могут быть проявлениями ухудшения течения сердечно-сосудистых заболеваний, непрямой кардиотоксичности или течения собственно онкологического процесса, поэтому требуется проведение своевременной дифференциальной диагностики, разработки стратегий профилактики, обоснованного лечения возникших сердечно-сосудистых нарушений и дальнейшего ведения больных. Для достижения этих целей необходимостью является организация междисциплинарных команд с участием кардиологов/кардиоонкологов и других специалистов, участвующих в работе междисциплинарных консилиумов.